Latest Market Growth News

4DMedical has won a crucial US Medicare reimbursement for its CT, VQ™ lung imaging software, paving the way for rapid adoption across American hospitals. This milestone follows FDA clearance and promises to transform lung diagnostics with safer, faster scans.

PolyNovo Limited stands to benefit from proposed U.S. Medicare changes that introduce a flat reimbursement rate for outpatient wound care skin substitutes, potentially reshaping the competitive landscape in favour of cost-effective, clinically proven products.

Bioxyne Limited delivered a record FY25 with $30.4 million revenue, driven by Australian market growth and new European contracts. The company projects revenue up to $75 million in FY26, fueled by expanded production and international market entries.

ECS Botanics reports a 5% revenue dip to $19.5 million in FY25 but sees strong B2C growth and record harvest volumes, offset by non-cash impairments.

Bubs Australia Limited reports a striking turnaround in FY25 with revenue up 29% to $102.5 million and net profit soaring 124% to $5.17 million, driven by strong US and China growth. The company awaits permanent FDA approval, a pivotal factor for its future trajectory.

PointsBet Holdings Limited reported a 6% increase in revenue to $261.4 million for FY2025, alongside a significant reduction in net loss and its first full year of EBITDA profitability. The company’s Australian operations delivered record results while Canadian growth accelerated, setting a positive trajectory for the future.

Cettire Limited reported FY25 results showing stable sales revenue and a breakeven adjusted EBITDA despite a challenging luxury goods market. The company’s strategic focus on profitability, supply chain expansion, and emerging markets diversification underpins its resilience.

NTAW Holdings Limited has delivered a strong second-half turnaround in FY2025, posting a $30.3 million Operating EBITDA despite a full-year net loss. Under new leadership, the company is setting the stage for consolidation and growth in FY2026.

Airtasker Limited reported a 12.8% increase in revenue to $52.6 million for FY25, driven by growth in Australia, the UK, and the US. However, the company’s net loss widened significantly to $37.7 million, reflecting heavy investment in global marketing and media partnerships.

SomnoMed delivered a strong FY25 performance with revenue climbing 22% to $111.5 million and EBITDA turning positive at $9.2 million, boosted by operational improvements and FDA clearance of its Rest Assure device. The company projects further growth in FY26 with expanded manufacturing and ongoing innovation.

Lynas Rare Earths has launched a fully underwritten A$750 million equity raising to fund its ambitious Towards 2030 growth strategy, aiming to expand rare earths production and downstream capabilities outside China.

Lynas Rare Earths reported FY25 results featuring record NdPr output and the first commercial heavy rare earths production outside China, alongside a $750 million equity raise to fund its ambitious Towards 2030 growth strategy.